Needs and Requirements of Modern Biobanks on the Example of Dystonia Syndromes by Ebba Lohmann et al.
January 2017 | Volume 8 | Article 91
HypotHesis and tHeory
published: 30 January 2017
doi: 10.3389/fneur.2017.00009
Frontiers in Neurology | www.frontiersin.org
Edited by: 
Alberto Albanese, 
Catholic University of the 
Sacred Heart, Italy
Reviewed by: 
Graziella Madeo, 
University of Rome Tor Vergata, 
Italy  
Renato Puppi Munhoz, 
Pontifícia Universidade Católica do 
Paraná, Brazil
*Correspondence:
Kathrin Grundmann 
kathrin.grundmann@ 
med.uni-tuebingen.de
Specialty section: 
This article was submitted to 
Movement Disorders, 
a section of the journal 
Frontiers in Neurology
Received: 03 May 2016
Accepted: 09 January 2017
Published: 30 January 2017
Citation: 
Lohmann E, Gasser T and 
Grundmann K (2017) Needs and 
Requirements of Modern Biobanks 
on the Example of Dystonia 
Syndromes. 
Front. Neurol. 8:9. 
doi: 10.3389/fneur.2017.00009
needs and requirements of Modern 
Biobanks on the example of dystonia 
syndromes
Ebba Lohmann1,2,3, Thomas Gasser2,3 and Kathrin Grundmann4*
1 Department of Neurodegenerative Diseases, Hertie Institute for Clinical Brain Research, University of Tübingen, Tübingen, 
Germany, 2 DZNE, German Center for Neurodegenerative Diseases, Tübingen, Germany, 3 Istanbul Faculty of Medicine, 
Department of Neurology, Behavioral Neurology and Movement Disorders Unit, Istanbul University, Istanbul, Turkey, 
4 Department of Medical Genetics and Applied Genomics, University of Tübingen, Tübingen, Germany
Dystonia belongs to a group of rare diseases (RDs) characterized by etiologic heteroge-
neity, affection often in childhood, severe and variable clinical manifestation. The burden 
of this disease is aggravated by the lack of effective and specific treatment. In the field 
of dystonia as in other RDs the number of available biospecimens is, in general, limited. 
Here, we report a new approach to collect clinical and genetic data in biospecimens main-
tained collaboratively by researchers and their associated institutions in a  decentralized 
system. Allowing researchers to have access to significant numbers of samples and 
corresponding clinical data, biobanking in dystonia might not only provide a powerful 
tool in the identification of disease genes but also the classification of variants detected 
in known genes with respect to their clinical relevance. Growing data in genetics due to 
the technical progress demand for well-annotated and well-managed biobanks, which 
in near future hold even the potential for biomarker research and generating medical 
treatment based on clinical and genetic data currently summarized as “personalized 
medicine.”
Keywords: biobank, rare disease, dystonia, genes, euro-dystonia
introdUCtion
Rare diseases (RDs), also called orphan diseases, of which there are approximately 5.000–8.000, 
are diseases that affect a small number of people compared to the general population, and specific 
issues are raised in relation to their rarity. They are often genetic in origin (1, 2). Specific challenges 
for health care and for research are the rarity and the heterogeneity of RDs. These also affect the 
development of therapies and their marketing. As a result, many patients with RDs do not receive a 
timely and accurate diagnosis (3, 4), have to consult numerous doctors to obtain a final diagnosis, 
and only few receive tailored treatment influencing survival and/or quality of life. It is because of 
these specific challenges that the EU Public Health Programme 2008–2013 has made RDs a priority 
area for action. A large number of RD-focused projects have been selected for under the Sixth and 
Seventh Framework Research Programmes (5). More recently, a proportion of Horizon 2020, one 
of the largest EU Research and Innovation programmes with a budget of almost 80 million Euro, is 
specifically aimed at RD initiatives (6). Experts now hope that on the basis of their genetic knowledge 
and pathway definition, they will be able to develop a new concept, often called “precision medicine.” 
This should change our view on how to apply therapeutic targets. Collecting clinical and genetic data 
taBle 1 | examples for dystonic syndromes.
Blepharospasm
Writer’s cramp
Spasmodic dysphonia
Cervical dystonia
Oromandibular dystonia
Meige syndrome
Myoclonic dystonia
Generalized dystonia
Rapid-onset dystonia-parkinsonism
Paroxysmal kinesigenic dystonia
Paroxysmal dystonia choreoathetosis
DOPA-responsive dystonia
Tardive dystonia
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and also biospecimens (biobanks) will become more important in 
the diagnosis and therapy development for RDs.
To look for an example of a RD, we should look at dys-
tonia. Dystonia is a hyperkinetic movement disorder and is 
 characterized by sustained muscle contractions with repetitive 
movements and also abnormal postures. It is difficult to establish 
specific information on the prevalence of dystonia because of 
the lack of a representative number of population-based studies. 
However, based on the current data, the overall prevalence of 
“primary” dystonia, an umbrella term describing a number of 
familial and sporadic forms of the disease, is calculated at 16.43 
per 100,000 (95% confidence interval: 12.09–22.32) (7).
In this article, our aim is to review the current situation and 
future direction of RD biobanks by looking at examples of dys-
tonic syndromes and discussing the research and development 
arising from the use of biospecimens, so as to improve the disease 
management.
deFinition oF tHe rare diseases 
dystonia
Rare diseases can manifest at any stage in life, though general-
ized or severe forms often start in early childhood. Common RD 
characteristics are genetic, severe, disabling, non-preventable, 
sometimes fatal, progressive, and having no specific effective 
treatments (8, 9). Recently, the Australian rare disease commu-
nity proposed a definition for RD as being “a life-threatening or 
chronically debilitating disease which is statistically rare, (with 
an estimated prevalence of less than 1 in 2,000 or of similarly 
low prevalence) and has a high level of complexity such that 
special combined efforts are needed to address the disorder or 
condition” (10).
Dystonia, a good example of a RD, meets this definition, even if it 
does not describe a specific disease or pathomechanism. Dystonia 
is a general term for a large group of movement disorders. These 
may vary in their symptoms, their causes, their progression, and 
their treatments (Table 1). Dystonia generally shows sustained or 
intermittent muscle contractions. These can cause abnormal and 
often repetitive movements and postures. Dystonic movements 
will often be patterned and twisting, may be tremulous, affecting 
the neck, the torso, the limbs, the eyes, the face, the vocal chords, 
and even a combination of these muscle groups. Dystonia can 
be initiated and worsened by voluntary action and is associated 
with overflow muscle activation (11). Dystonic postures may 
cause varying degrees of pain and disability. These can range from 
occasional and mild symptoms to severe, debilitating symptoms, 
significantly affecting a person’s quality of life. Dystonia can 
become progressively worse but remains unchanged in some 
cases. In rare cases, it has been known to spontaneously remit. 
Treatment will depend on several factors, e.g., specific subtype 
and can include medication, botulinum toxin injections, physical 
therapy, or even surgery.
Although various elements can contribute to the develop-
ment of dystonia, in many cases, the exact, underlying causes 
are unknown. Despite the etiological heterogeneity, the thematic 
similarities apparent across the dystonic syndrome natural 
history spectra do enable coordinated approaches. It has been 
shown, for example, that genetic factors play an important role in 
the development of dystonic syndromes (12). However, obtaining 
a genetic diagnosis for dystonia is often difficult because of the 
lack of appropriate diagnostic tests. A diagnosis is important for 
the affected patient and his family, though, even when available, 
the costs of validated tests are not always covered by insurance 
companies. This is despite the fact that molecular characteriza-
tion of the sample being critical to a correct diagnosis. This would 
provide patients with specific genetic counseling, subsequent bet-
ter care and follow-up. Another important aspect of the genetic 
diagnosis is its use in research, e.g., giving thought-provoking 
impulses in order to develop models of the pathomechanism 
involved (13). Samples, however, are currently only available 
through highly specialized centers and are stored in a particular 
system for a population because of the specific research involved.
tHe disCipline oF BioBanKinG
Recently, the paradigm in medicine of “reactive approaches” 
centered on disease therapy is moving to a more personalized, 
prognostic, preventative, and contributing approach, focusing on 
the conservation of health (14). This development is promoted by 
advances acquired from sequencing of the whole human genome 
and the rapid development in bioinformatics and analytical 
laboratory technologies (15). Biobanks, as repositories for the 
storage of this biological material and its corresponding data, 
could become important tools and instruments in driving this 
change in the way health care is delivered.
Instead of the subdivision of complex biological phenom-
ena, interdisciplinary efforts are actually made to address the 
substantial complexities of human biology and medicine. In 
these young scientific disciplines, advanced mathematical and 
statistics strategies support the research into the interactions 
of individual biological elements. These systems not only can 
retrospectively analyze biological parameters but can also 
model in silico different interactions. Systems biology research 
combines “wet laboratory” experimentation with “dry labora-
tory” predictions of the biological processes (14, 15). All these 
developments, which took off approximately a decade ago, have 
helped establish organized biobanking (16, 17). The develop-
ment of guidelines for the standardization of workflow methods 
taBle 2 | Biobank designs.
Biobank Characteristics
Population-based Find the biomarkers for disease susceptibility within a specific population through prospective molecular epidemiology research.
Recruitment of healthy donors, typical of a region, country, or specific ethnicity.
DNA isolated from venous blood is the most commonly stored biospecimen.
Associated data comprising medical history, physical measurements, and epidemiological data (e.g., lifestyle habits, socioeconomic status).
Disease-
orientated
Collection of biological materials, collected within the context of clinical care.
Patients will only provide biological material and will eventually provide more samples at follow-up visits during the course of their treatment.
A number of different disease-oriented biobank subtypes exist.
Case–control A selection of matched (age and sex as a minimum) individuals presenting a given disease. These will be matched with compatible healthy controls.
Epidemiological case–control studies can be used as biobanks.
Population-based biobanks can provide case–control.
Tissue banks Extremely diverse collections of tissue specimens.
Usually invasive sampling followed by cryopreservation.
Detailed information on the nature of the underlying disease.
Specific form of tissue banks, e.g., formalin-fixed paraffin-embedded specimen collections.
Biobanking 
within the 
context of 
clinical trials
Performed by research organizations and/or investigator-driven clinical trials.
Associated with complex clinical and laboratory monitoring data. Examine samples (e.g., blood, urine), which can in turn be integrated into a biobank 
and used for research.
Aim is to identify disease/trial-associated biomarkers.
Other specific 
biobanking 
formats
Specific methods are necessary requiring deep experience (e.g., cell cultures of pluripotent cells).
Specific research goals (Guthrie cards).
Commercial interest with the regard to future regenerative therapies (cord blood).
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that ensure sample quality and stability is ongoing (18). When it 
comes to the future of human medicine and particularly to that 
of RDs such as dystonia, biobanking may hold the key, and the 
standardization of biobanking workflows will ensure a promis-
ing future.
tHe Field oF BioBanKinG
Biobanks will typically:
 – collect and store biological materials. These should be labeled 
not only with medical data but also with epidemiological data 
(e.g., environmental exposure, lifestyle, and occupational 
information);
 – not be static “projects,” as biological materials and data are 
generally collected on a continuous or long-term basis;
 – be associated with current (defined) or future (not yet speci-
fied) research projects at the time of biospecimen collection;
 – apply encoding or be anonymous to ensure donor privacy 
though under certain circumstances will allow the participants 
to remain identifiable in order to provide clinically relevant 
information back to the donor;
 – include established governance structures (e.g., ethics review 
committees) and procedures (e.g., consent) that serve to 
protect donors’ rights and stakeholder interests.
The field of biobanking is, generally speaking, very heteroge-
neous (16, 17). Although it is difficult to list all distinguishing 
characteristics of biobanks exhaustively, there are some that can 
be used to characterize different types of biobanks. These are 
size, research design, the types of biological samples collected, 
the method of sample collection, processing and storage, and the 
disease/research focus. These characteristics will influence the 
scope of biobank activities, such as the recruitment of donors, the 
consent procedures, the scale of IT support needed, the structure 
of its administration, and the potential for commercial usage. 
In the past, the terminology describing organized collections 
in medicine has not been consistent. Various terms have been 
in use to refer to activities involving biobanks/biobanking, such 
as “human genetic research databases (HGRDs),” “population 
genetic databases,” “biorepositories,” or “tissue banks.” However, 
the term “biobank” has now been established.
Multiple biobank formats can be found within the context 
of medical research. These can be differentiated, based on their 
design and scientific aim (Table 2). However, all biobank formats 
are linked in some form and, to a certain degree, represent a 
continuum within the infrastructure supporting all steps in the 
biomedical research “pipeline” (16, 17).
BioBanKs For dystonia
It is important to access biological materials for scientific research 
in all medical fields and particularly for research on RDs such as 
dystonic syndromes, though it is difficult to obtain high quality 
samples and related clinical data. Biobanks play a major role in 
providing such materials and data to the scientific community.
Nevertheless, up to date, it is difficult to determine the exact 
number, nature, and quality of samples from patients with dys-
tonic syndrome included in the various biobanks.
An example of a large initiative that is currently run-
ning for the study of dystonia is the “Dystonia Coalition” 
funded by the National Institutes of Health, USA and aims 
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to establish a centralized biobank of samples for the study of 
dystonic syndromes. More than 40 participating clinical centers 
are  distributed throughout North America and Europe.1
The European counterpart is the Europe Dystonia (ED) 
group, a group of researchers who have developed a web-based 
integration of their research activities on the genetics of dystonia.2 
The ED research network presently consists of partners from 16 
European countries and Israel. The ED registry and biobank is a 
collaborative network project supported by all members of the 
ED research network. It consists of a web-based registry for clini-
cal and genetic data, hosted by the University of Tübingen, and a 
decentralized biorepository at different research sites.
The structure and the organization of the ED registry fulfill all 
the requirements of a modern and sustainable biobank system, 
and in the following sections, the biobank will be explained in 
more detail.
european dystonia registry  
and Biorepository
Organization
The network includes two types of participating centers, 
depending on local resources and interests: “Collection only” 
centers and “Collection-DNA storage” centers. The “Collection 
only” centers include all Euro-dystonia centers willing to collect 
clinical data, enter them into the Clinical Dystonia Registry 
in a standardized way, and draw blood for DNA extraction on 
patients with dystonia and their consenting relatives, but with 
no facilities for DNA extraction or storage. In comparison, 
the “Collection-DNA storage” centers perform all tasks of the 
“Collection only” center, but, in addition, extract and store sam-
ples, grow cells, and make the biospecimen available for research. 
This combination of centralized and decentralized biobanking 
combines in a perfect way the strengths of both models: high 
quality in the control of biospecimens, data management, and 
operation via standardized and harmonized methods of samples 
extraction and storage between the collecting centers. This 
combination of both systems is faster, more likely to preserve as 
many analytes as possible, is suitable for very complex protocols, 
and leaves space for flexibility and innovation without incurring 
high setup or transport costs.
Data Handling
Protection of personal data is ensured according to local legal 
regulations. DNA, personal data, and genetic data are only 
documented, stored, and analyzed anonymously. Identification 
of samples and patients may be necessary in order to obtain 
additional clinical information or to inform the patient that 
clinically relevant results have been obtained. Identification 
lists are only available to an authorized clinical investigator at 
the participating center. Local ethics boards have to approve all 
procedures. It is important to correlate data and biospecimens 
from different biobanks, this being crucial in accelerating the 
pace of translational research. A process of harmonization is 
1 http://www.rarediseasesnetwork.org/dystonia.
2 http://dystonia-europe.org.
crucial in order to share the best practices and procedures in 
biobanks. This more flexible approach aims at ensuring the effec-
tive interchange of valid information and samples (19).
All patients and relatives must be fully informed about the 
study, in particular, about the voluntary nature of participation and 
the possibility of withdrawing and having the sample destroyed, 
at any time. Depending on the local procedure based on the local 
ethical approval, patients and relatives are also informed that no 
individual test results will be given, but that information about 
research results in general can be obtained from the attending 
physician at the ED center. If clinical genetic testing should 
become available, based on results of the scientific studies, and 
the patient has chosen on the consent form to be informed, a 
formal testing procedure may be suggested to the patient and 
its relatives according to general guidelines for genetic testing 
at a certified laboratory. The general procedure in reporting the 
results of the findings from the use of biospecimens is publishing 
these for the benefit of the scientific community. Findings that 
fall outside the research objectives and that have potential health 
or clinical significance are termed “incidental finding” (20). A 
debate has recently emerged over the need to return incidental 
findings, and policies are rapidly being developed to cover actual 
and future obligations (21). Nevertheless, a harmonized and 
ethically defensible plan for the return of incidental findings is 
not yet available, and the final decision is taken according to the 
evaluation of the responsible clinician.
Ownership
Ownership of (personal) data is a very important issue. Since there 
are obviously numerous stakeholders in a biobank—the donors, 
the investigators, the funding agencies, the institution housing 
the bio-samples, and the ethics review committee—it has been 
proposed that the institution of the biobank should hold “custo-
dianship” for the use of the resource, and that, as custodian of the 
samples, should carry numerous responsibilities (22). However, 
the members of the European Dystonia Registry and Biorepository 
concluded that clinical data and biomaterials remain in the pos-
session of the donor unless national legal regulations determine 
differently.
Data and Biomaterial Access
All data and DNA-samples are accessible at all times available 
with no restrictions for the participating centers. Pseudonymized 
data and DNA-samples are made available to other researchers 
upon request according to the procedure detailed below. A steer-
ing committee has been elected by the majority of the votes of 
all participating centers of the ED and deals with questions of 
distribution of the DNA resources for scientific projects on the 
basis of the procedure outlined below.
Use of Samples
Samples can also be made available to research groups within and 
outside the ED collaboration. For example, in the case of dystonia, 
the samples will be used for the study of possible genetic factors 
in the development and course of the disease, and a research 
proposal will be submitted to the ED steering committee. The 
committee then submits a recommendation to the contributing 
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center based on the scientific merits of the proposal. The steer-
ing committee will ensure that all laboratories receiving samples 
from ED agree in writing that
•	 samples will be used only for the project applied for;
•	 samples will not be passed on to other laboratories without 
express permission; and
•	 an appropriate publication policy will be guaranteed.
However, the final decision on the use of samples will 
remain with the local contributing scientists. Contributors will 
be informed about all study proposals and sample allocations. 
In some cases, fees can be charged for the maintenance of the 
biobank.
In addressing the social and ethical challenges of biobanking 
(23), proper governance is vital to the success of biobanking 
initiatives: it is crucial in ensuring the safety and protection of 
participants, in preserving public support and financing, and 
in safeguarding the availability of biospecimens for research 
(24,  25). This is especially applicable to RD biobanking efforts 
because of the rarity and diversity of biomaterials and the role 
played by patients and patient organizations (13).
Scientific Publications
A major challenge is in how to honor and recognize the effort and 
the expertise involved in establishing a biobank. Until recently, 
there was a direct link between the researcher who set up a data 
set and the background for many publications. This relationship 
in biobanking, between the custodian and the biobank, is very 
different, as the biobank has been established as a resource open 
to others. The custodian of the biobank may or may not, carry out 
research on material from the biobank. Therefore, the traditional 
ways of acknowledging researchers through their publications, 
which may further their careers, become difficult for the custo-
dians of biobanks. Many journals require that data production 
should be acknowledged, but how this is done is largely left up 
to individuals who follow the norms that exist in their particular 
discipline (26).
If results of scientific studies based on the ED collaboration 
are published, according to good scientific practice, authorship 
is based on individual contributions. In accordance with the 
published guidelines of scientific journals, contribution of a lim-
ited number of DNA-samples alone is not necessarily sufficient 
to justify coauthorship. However, regarding all papers based on 
the use of ED samples, it is proposed to include the following 
sentence: “and members of Euro-Dystonia Network,” with at 
least one representative of each participating center, which has 
provided DNA, being listed in an appendix. An accepted signifi-
cant scientific contribution, justifying coauthorship, would be the 
contribution of a substantial number of samples with thorough 
clinical data documentation. This contribution is admittedly hard 
to evaluate and would need to be assessed case by case.
BeneFits and CHallenGes oF 
BioBanKs For dystonia
Biobanks for dystonia support the adaptation of laboratory 
research into clinical applications, the defined goal being to 
harmonize diagnostic or therapeutic tools for the disease (13, 
27). In dystonia, with valuable but limited amounts of biomate-
rial scattered over a large area, biobanks are a major resource. 
The purpose of the biobank very much determines its benefits. 
The purposes vary greatly from generating revenue, supporting 
scientific discoveries and the understanding the causes of the 
disease, genetic testing, assessing drug efficacy and treatment, 
identifying new genes and biomarkers, clinical trials, education, 
or personalized therapy. Biospecimens held in biobanks have 
helped researchers and clinicians in their understanding of the 
mechanism and underlying causes, particularly of RDs, and have 
also helped with gene identification and the development of 
diagnostic and therapeutic biomarkers. New genes and new gene 
mutations have been discovered, thanks to collections of DNA 
(28–31), as has the development of new diagnostic criteria (32), 
and the defining of genotype–phenotype correlations (33, 34). 
Analysis of serum and of plasma has facilitated the identifica-
tion of new biomarkers (35, 36) and protein profiles (37). Other 
biospecimens, such as mRNA, stem cells, and tissue, have helped 
to collect functional data in order to identify other pathways and 
new therapies to be applied to RDs (38–40).
Three major challenges need to be met in order to increase 
the effectiveness of biobanks for dystonia: maximizing access for 
the international scientific community to rare biological samples 
stored in biobanks across the globe, promoting networking among 
such biobanks in order to share and harmonize quality standards 
and procedures and allowing collaboration with dystonia regis-
tries and databases, and finally adopting an efficient management 
model compliant with legal and ethical issues, ensuring biobank 
sustainability.
Historically, research in dystonia has been highly fragmentary, 
according to data type, research institution, or dystonic syn-
drome. There is a limited number of biospecimens for most types 
of dystonic syndromes, and it may be difficult or impossible to 
increase the sample number in a short time frame, making these 
samples extremely precious. Additionally, to achieve usefulness, 
the quality of the biomaterials and of the associated information 
is of primary importance (27). Some research biobanks held in 
laboratories with non-interoperable databases can make it almost 
impossible to connect genetic data with detailed clinical informa-
tion or biospecimen availability.
To achieve this, it is important to increase the awareness of dys-
tonia, to increase the number of dystonia registries and biobanks 
accessible to concerned patients and families, and to expand the 
availability of biospecimens from these patients. In this context, 
it is notable that the attitudes toward biobanks are still far from 
being settled in many countries. In general, there is a cluster of 
Northern European countries where the prospect of biobank 
research is greeted enthusiastically, whereas the general public 
of many Central and Southern European countries is generally 
more reserved about biobank research, providing tissue samples 
and granting broad consent for research (41). This reserve has 
implications for recruitment and also for the running and gov-
ernance of biobanks. Another particularity with decentralized 
international biobank network for dystonia is the fact that ethical 
guidelines and the patient’s attitude toward biobanks often differ 
widely between different countries (42). At the outset, all ethical 
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considerations should be in line with national guidelines of the 
patient’s country and where the biomaterial has been obtained. 
However, there exists no global consensus regarding the shar-
ing of biomaterial and data. Eventually, consent will move on 
to becoming ongoing and dynamic; participants will be able to 
engage as much as they wish and to change their consent choices 
over time (20).
tHe GenetiC aspeCt
Dystonia is also a very challenging disease from a genetic point of 
view. First, a number of clearly genetic conditions are still unde-
fined. Second, penetrance of mutations in known genes is low. 
Third, we observe a broad phenotypic variability in the major-
ity of mutations in known genes. In conclusion, the predictive 
value of mutations in known genes is low. Even if the mutation is 
known, we cannot tell whether the person will be affected, and if 
affected, how seriously. Furthermore, in some countries, prenatal 
diagnosis is not allowed for mutations with reduced penetrance 
and uncertain clinical prognosis.
On the other hand, with the introduction of the next-
generation sequencing, sequencing of the whole genome in 
an affordable time frame is now possible. Accordingly, next-
generation sequencing increases the pace of discovery of novel 
genes, even in RDs, tremendously (43). As genetic sequencing 
becomes cheaper and more accessible, we are about to face 
an increase of genetic tests in dystonia and subsequently, an 
increase in unclear variants. In particular, analysis of genes in 
RDs leads to results associated with extremely limited informa-
tion about penetrance, phenotype, and prevalence. Moreover, 
Bell and colleagues recently observed that a high proportion 
of disease mutations (27%) are incorrectly or incompletely 
annotated (44). Thus, for many recessive orphan diseases, 
standard open accessible databases such as HGMD, dbSNP, or 
OMIM provide insufficient information (44). Identification of 
potentially underlying genetic causes by means of comprehen-
sive analysis of gene sequences is technically feasible though 
the clinical interpretation of the functional importance or of 
the pathogenicity of variants will be challenging for numerous 
genetic diseases and would require the establishment of an 
authoritative disease mutation database. Otherwise, the clinical 
usefulness of comprehensive carrier testing will be limited. The 
benefit of a transnationally organized biobank, including the 
molecular characteristic and also results of clinical and para-
clinical examinations of the patients and their family members, 
is based on greater flexibility, particularly regarding the genetic 
approach. This is mainly because they can support a variety 
of studies, including cross-sectional studies of genotype–phe-
notype correlations, case–control studies using a biobank for 
cases and/or controls, and cohort studies using baseline and 
follow-up data in a biobank to link genetic variation with health 
outcomes (45).
FUtUre perspeCtiVes
Bringing dystonia biobanks to the attention of scientists, clini-
cians, and patients will require further efforts. These will also 
be necessary in order to closely link and receive information 
from specialized diagnostic centers and disease experts, for 
further qualitative and quantitative progress. It is important 
that clinical staff should have a clear understanding of the 
added value of participating in the biobank network. They 
should be encouraged to collect samples and to update relevant 
databases. These efforts are a generous contribution to global 
health research, but they are also a direct path to advancing 
personal scientific and medical activities (46). It is important 
to establish an accreditation and evaluation system so as to 
acknowledge biobanks providing high quality samples and to 
reward and recognize the scientists who establish and maintain 
biobanks.
Here, the promotion of collaboration between biobanks and 
patient associations will not only help collect more samples 
and associated data and furnish them to researchers but could 
also help address the ethical and legal challenges, thanks to the 
underlying agreements based on solidarity.
Sustainability is another important issue facing dystonia 
biobanking. The pharmaceutical industry, clearly, has little 
interest in funding small biobanks that contain and exchange 
small numbers of samples, making specific funding for dystonia 
biobanks essential. An approach to this problem could be the 
implementation of a business model in which both cost and 
revenue are examined. However, the commercialization of the 
biobank biomaterial and/or clinical data is not always a feasible 
option. National or institutional regulations, ethical guidelines, 
or patients refusing informed consent, all prevent any com-
mercialization and limit the willingness of the pharmaceutical 
industry to get involved.
In order to unify and simplify the practice of biobanking 
across multiple institutions and different countries, it would 
be essential to harmonize the legal and regulatory frameworks 
that apply. Additionally, interoperability and harmonization of 
dystonia patient registries and dystonia biobanks are critical for 
linking data, together with time-efficient procedures adapted 
to the clinical workflow promoting clinical engagement and 
enhancing diagnostic and therapy development for dystonic 
syndromes.
ConClUsion
The challenge for the future of biobanking in RDs as dystonia 
is how to develop governance that encourages a sustainable 
international biobanking infrastructure. Presently, the regula-
tory systems are not harmonized, thus hindering straightforward 
sharing of samples and data in an ethical and legally compliant 
manner across national borders. This does not aid cutting-edge 
research across borders in the most efficient and economical 
manner. The governance structure for medical research needs 
to move from being designed around “one-researcher, one-
project, one-jurisdiction” model to enable the flow of samples 
and data between biobanks as part of regional/global networks 
for research. One way to achieve this is to use information 
technology to develop e-governance systems that can increase 
the transparency of the research done and augment existing 
expert committee review and national systems of oversight. This 
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will enable dystonia biobanks to become component parts of 
the health-care structure and a tool to enhance a personalized 
medicine approach to health care, respecting the participants’ 
fundamental rights and researchers’ needs. All future develop-
ments should take account of other efforts undertaken elsewhere 
in the world.
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